Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Intratumoral Cancer Therapies Market Snapshot (2023 to 2033)

The global Intratumoral Cancer Therapies market is expected to garner a market value of US$ 212.96 Billion in 2023 and is expected to accumulate a market value of US$ 552.36 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033. The growth of the Intratumoral Cancer Therapies market can be attributed to favorable regulatory frameworks for cancer treatments. The market for Intratumoral Cancer Therapies registered a CAGR of 7% in the historical period 2017 to 2022.

Cancer is among the top causes of mortality worldwide, and its incidence is increasing at an alarming rate. As a result, healthcare experts are concentrating on the development of efficient treatment and diagnosis solutions in order to reduce the incidence level. Early detection improves treatment regimen success rates. As a consequence, healthcare institutions and industrial companies are pushing routine exams through different awareness efforts.

Report Attribute Details
Expected Market Value (2023) US$ 212.96 Billion
Anticipated Forecast Value (2033) US$ 552.36 Billion
Projected Growth Rate (2023 to 2033) 10% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Intratumoral Cancer Therapies Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Intratumoral Cancer Therapies reflected a value of 7% during the historical period, 2017 to 2022. National lockdown, government controls, and a spike in infection rates across countries all had a major financial impact on neurological clinics and hospitals. Several clinics and hospitals have seen a decrease in patient visits as a result of COVID-19, thereby minimizing client engagement.

Many cancer diagnoses have been pushed back as a result of the COVID-19 dilemma. There was a global shortage of medical treatment for disorders other than COVID-19, which has had a detrimental influence on the Intratumoral Cancer Therapies business. Also, the restricted availability of healthcare personnel throughout the world is another aspect that has a negative impact on the Intratumoral Cancer Therapies industry.

However, post the pandemic, the complication in various people have increased. People suffering from even stage 1 cancer faced complications as the effects of the virus affected the immune system gravely. This paced up the demand for cancer therapies and also made the companies expand the product portfolio to provide enhanced immunity to the patients.

Thus, the market for Intratumoral Cancer Therapies is expected to register a CAGR of 10% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Intratumoral Cancer Therapies Market?

Increasing incidence of cancer to push the market growth

According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers, globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. The increasing incidence of cancer across the globe has been rapidly adding to the growth in the field of cancer research.

In April 2020, the US FDA approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer. Furthermore, in May 2020, the US FDA approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer (NSCLC), and it is the first FDA-approved targeted therapy to treat NSCLC with specific mutations. Thus, the high research activities related to targeted therapies against cancers are expected to grow over the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Intratumoral Cancer Therapies Market?

Strict Regulations and Higher Costs to restrict Market Growth

Inadequate reimbursement regulations are predicted to restrain market expansion. In recent years, there have been several developments in the cancer therapy industry. However, most medical insurance companies do not cover procedures that use computer-aided detection (CAD). As a consequence, individuals choose traditional diagnostic methods such as biopsies, and pathology tests, or conventional imaging methods such as mammography and MRI treatments. Furthermore, the high cost of intratumoral cancer therapy is projected to stifle market expansion.

Region-Wise Insights

How is the Adoption of the Intratumoral Cancer Therapies Market in Europe Turning Out?

Increased government funding propelling the growth of Intratumoral Cancer Therapies in Europe

The European market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period. Europe is estimated to be the fastest-growing region over the forecast period due to an increase in research funding by government bodies to help combat the growing incidence of cancer cases across the region. In addition, the existence of major players promotes expansion in the United Kingdom. These firms' strategies include new releases and growth initiatives, which will continue to help overall expansion in Europe.

In addition to this, the European Union’s ‘Horizon Europe Mission on Cancer’ was launched in September 2021 to offer funds to a broad spectrum of activities that are intended to lower Europe’s cancer burden by accelerating research and innovation in cancer therapeutics. The mission is anticipated to help over 3 million cancer survivors by the year 2030.

What are the Factors Boosting the Market for Intratumoral Cancer Therapies in North America?

High Concentration of Key Players shaping the landscape for Intratumoral Cancer Therapies in North America

North America is expected to increase its market share in the future, owing to the increased adoption of cancer therapy and the growing burden of cancers in the USA. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the USA in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the USA.

In terms of market share and revenue, the North American market is predicted to be the most lucrative market during the forecast period with a revenue share of 40%. One of the primary factors propelling the industry in the region is the presence of various biotechnology and medical device firms. North America is likely to maintain its lead during the projection period due to factors such as increased spending for Research and Development initiatives and widespread use of new technology.

The region's high concentration of important players, growing FDA approvals, strategic partnerships, and substantial expenditure in research & development activities are projected to enhance the market. For instance, in November 2020, Merck & Co. Inc entered into a definitive agreement to acquire Velosbio Inc., which is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).

Thus, given the aforementioned factors, the cancer therapy market is expected to grow significantly over the forecast period in North America.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Based on Technology, Which Segment is Pushing the Market Growth?

The superior efficiency of checkpoint inhibitors bolsters the growth

On the basis of technology, the checkpoint inhibitors segment is estimated to witness the highest CAGR. The high growth can be attributed to the benefits offered by this therapeutic drug. Furthermore, the increasing product approvals by the regulatory authorities are expected to contribute to the market's growth. For instance, in August 2021, FDA approved the Glaxosmithkline PD-1 checkpoint inhibitor Jemperli (dostarlimab) for adults with mismatch repair-deficient recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

By Application, Which Segment Dominates the Market?

Increased incidence of lung cancer to drive market growth

By application, lung cancer is estimated to account for the largest share of the market. Due to the increasing number of patients suffering from lung diseases, the lung cancer segment is expected to hold the largest share in the next ten years as well. Increasing incidences of lung cancer due to the rising smoking population is one of the major factors driving the growth of the lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers.

The market is being driven by a growing demand for tailored therapy, the availability of highly effective medications, an increase in the elderly population, and an increase in the prevalence of unhealthy lifestyles.

Start-up in the Intratumoral Cancer Therapies Market

Key start-up players in the Intratumoral Cancer Therapies market are-

  • Race Oncology is an ASX-listed precise oncology firm that is developing Zantrene®, a Phase 2/3 cancer medication. Zantrene® is a powerful fatso/fat mass and obesity-linked (FTO) protein inhibitor. Overexpression of FTO has been identified as a genetic driver of a variety of malignancies. Race is investigating the potential of Zantrene® as a novel treatment for melanoma and clear cell renal cell carcinoma, two malignancies that frequently over-express FTO. In groundbreaking preclinical research, Race revealed that Zantrene® protects against anthracycline-induced heart damage while also functioning in combination with anthracyclines to boost their capacity to target breast cancer. Race is assessing this discovery.
  • Carer, which was founded in 2018, aims to improve the quality of life of every cancer patient in the convenience of their own home. It attempts to give patients with the best degree of support and therapy both during and after treatment to help recovery. Their therapy has a significant benefit in that it can be tailored to each patient's diagnosis, prior health difficulties, and chosen lifestyle, making it more feasible in the long run. This is accomplished through their three-pronged approach, which includes a dietary protocol, a movement and meditation protocol, and a mental well-being protocol that educates and motivates patients and caregivers to make life-changing adjustments for more successful healing.

Market Competition

Key players in the Intratumoral Cancer Therapies market are Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Johnson & Johnson, and Eli Lily Company, F.

  • Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the USA in 2022. The drug business stated in a statement that it has released the medicine in the US market through a partner who has acquired permission from the US Food and Drug Administration (USFDA). The business claims that its medicine is medically similar to Velcade for Injection from Takeda Pharmaceuticals. Bortezomib for Intravenous is used to treat cancers such as myeloma and mantle cell lymphoma.
  • Bristol-Myers Squibb K.K. announced in 2022 that the Japanese Ministry of Health, Labour, and Welfare had approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with refractory or relapsed (R/R) multiple myeloma who had received a minimum of three prior therapies. In Japan, Abecma was the first CAR T cell therapy licensed for treating R/R multiple myeloma in 2021. In Japan, Abecma is the first CAR T cell therapy licensed for treating R/R multiple myeloma in 2021. Bristol Myers Squibb is currently the only firm in Japan with two authorized CAR T cell therapies: the CD19-directed Breyanzi, which was approved in March 2021, and the BCMA-directed Abecma.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 212.96 Billion
Market Value in 2033 US$ 552.36 Billion
Growth Rate CAGR of 10% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • End-Users
  • Application
  • Technology
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa (MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Argentina
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASIAN
  • GCC
  • South Africa
Key Companies Profiled Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Johnson & Johnson, and Eli Lily Company, F.
Customization Available Upon Request

Key Segments Profiled in the Intratumoral Cancer Therapies Industry Survey

Technology:

  • Monoclonal Antibodies
  • Vaccines
  • Checkpoint Inhibitors
  • Cell Therapies
  • Immune System Modulators
  • Adoptive Cell Transfer
  • Cytokines

Application:

  • Lung Cancer
  • Breast Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others

End-users:

  • Hospitals
  • Cancer Research Centres
  • Clinics

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa (MEA)

Frequently Asked Questions

At what rate did the Intratumoral Cancer Therapies market flourish from 2017 to 2022?

From 2017 to 2022, the Intratumoral Cancer Therapies market grew at a CAGR of 7%.

What will be the growth rate of the global Intratumoral Cancer Therapies market during the forecast period?

The global Intratumoral Cancer Therapies market is expected to grow with a 10% CAGR from 2023 to 2033.

What will be the projected market size of the Intratumoral Cancer Therapies market by 2033?

As of 2033, the Intratumoral Cancer Therapies market is expected to reach US$ 552.36 Billion

Which technology segment is expected to dominate the global Intratumoral Cancer Therapies market during 2033?

Checkpoint inhibitors segment is poised to register the highest growth rate through 2033

Which type of application is expected to dominate the global Intratumoral Cancer Therapies market during 2033?

The Intratumoral Cancer Therapies market from the lung cancer application is predicted to observe the highest growth though 2033.

How is the North America Intratumoral Cancer Therapies market projected to grow in 2033?

North America is expected to possess 40% market share for Intratumoral Cancer Therapies market in North America.

How is the European Intratumoral Cancer Therapies market projected to grow in 2033?

The European market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

Table of Content

1. Executive Summary | Intratumoral Cancer Therapies Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        5.3.1. Lung Cancer

        5.3.2. Breast Cancer

        5.3.3. Colorectal Cancer

        5.3.4. Melanoma

        5.3.5. Prostate Cancer

        5.3.6. Head & Neck Cancer

        5.3.7. Others

    5.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Technology Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology Type, 2023 to 2033

        6.3.1. Monoclonal Antibodies

        6.3.2. Vaccines

        6.3.3. Checkpoint Inhibitors

        6.3.4. Cell Therapies

        6.3.5. Immune System Modulators

        6.3.6. Adoptive Cell Transfer

        6.3.7. Cytokines

        6.3.8. Others

    6.4. Y-o-Y Growth Trend Analysis By Technology Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Technology Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

        7.3.1. Hospital

        7.3.2. Cancer Research Centres

        7.3.3. Clinical

    7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States of America

            9.2.1.2. Canada

        9.2.2. By Application

        9.2.3. By Technology Type

        9.2.4. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Application

        9.3.3. By Technology Type

        9.3.4. By End Users

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Application

        10.2.3. By Technology Type

        10.2.4. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Application

        10.3.3. By Technology Type

        10.3.4. By End Users

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Application

        11.2.3. By Technology Type

        11.2.4. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Application

        11.3.3. By Technology Type

        11.3.4. By End Users

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Application

        12.2.3. By Technology Type

        12.2.4. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Application

        12.3.3. By Technology Type

        12.3.4. By End Users

    12.4. Key Takeaways

13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Application

        13.2.3. By Technology Type

        13.2.4. By End Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Application

        13.3.3. By Technology Type

        13.3.4. By End Users

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. United States of America

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Application

            14.1.2.2. By Technology Type

            14.1.2.3. By End Users

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Application

            14.2.2.2. By Technology Type

            14.2.2.3. By End Users

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Application

            14.3.2.2. By Technology Type

            14.3.2.3. By End Users

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Application

            14.4.2.2. By Technology Type

            14.4.2.3. By End Users

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Application

            14.5.2.2. By Technology Type

            14.5.2.3. By End Users

    14.6.United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Application

            14.6.2.2. By Technology Type

            14.6.2.3. By End Users

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Application

            14.7.2.2. By Technology Type

            14.7.2.3. By End Users

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Application

            14.8.2.2. By Technology Type

            14.8.2.3. By End Users

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Application

            14.9.2.2. By Technology Type

            14.9.2.3. By End Users

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Application

            14.10.2.2. By Technology Type

            14.10.2.3. By End Users

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Application

            14.11.2.2. By Technology Type

            14.11.2.3. By End Users

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Application

            14.12.2.2. By Technology Type

            14.12.2.3. By End Users

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Application

            14.13.2.2. By Technology Type

            14.13.2.3. By End Users

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Application

            14.14.2.2. By Technology Type

            14.14.2.3. By End Users

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Application

            14.15.2.2. By Technology Type

            14.15.2.3. By End Users

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Application

            14.16.2.2. By Technology Type

            14.16.2.3. By End Users

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Application

            14.17.2.2. By Technology Type

            14.17.2.3. By End Users

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Application

            14.18.2.2. By Technology Type

            14.18.2.3. By End Users

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Application

            14.19.2.2. By Technology Type

            14.19.2.3. By End Users

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Application

            14.20.2.2. By Technology Type

            14.20.2.3. By End Users

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Application

        15.3.3. By Technology Type

        15.3.4. By End Users

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Amgen Inc

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. AstraZeneca

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Bayer AG

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Bristol-Myers Squibb Company

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Pfizer Inc

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Novartis AG

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Johnson & Johnson

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Eli Lilly Company

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. F. Hoffmann-la Roche Ltd

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Seattle Genetics Inc

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Technology Type, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Technology Type, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Technology Type, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Technology Type, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 19: Asia Pacific Market Value (US$ Million) Forecast by Technology Type, 2018 to 2033

Table 20: Asia Pacific Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 21: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 23: MEA Market Value (US$ Million) Forecast by Technology Type, 2018 to 2033

Table 24: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Application, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Technology Type, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End Users, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Technology Type, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Technology Type, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Technology Type, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 17: Global Market Attractiveness by Application, 2023 to 2033

Figure 18: Global Market Attractiveness by Technology Type, 2023 to 2033

Figure 19: Global Market Attractiveness by End Users, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Application, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Technology Type, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Technology Type, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Technology Type, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Technology Type, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 37: North America Market Attractiveness by Application, 2023 to 2033

Figure 38: North America Market Attractiveness by Technology Type, 2023 to 2033

Figure 39: North America Market Attractiveness by End Users, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Application, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Technology Type, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Technology Type, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Technology Type, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Technology Type, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Application, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Technology Type, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End Users, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Application, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Technology Type, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by End Users, 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Technology Type, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Technology Type, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Technology Type, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 77: Europe Market Attractiveness by Application, 2023 to 2033

Figure 78: Europe Market Attractiveness by Technology Type, 2023 to 2033

Figure 79: Europe Market Attractiveness by End Users, 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033

Figure 82: Asia Pacific Market Value (US$ Million) by Technology Type, 2023 to 2033

Figure 83: Asia Pacific Market Value (US$ Million) by End Users, 2023 to 2033

Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Technology Type, 2018 to 2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Technology Type, 2023 to 2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Technology Type, 2023 to 2033

Figure 94: Asia Pacific Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 97: Asia Pacific Market Attractiveness by Application, 2023 to 2033

Figure 98: Asia Pacific Market Attractiveness by Technology Type, 2023 to 2033

Figure 99: Asia Pacific Market Attractiveness by End Users, 2023 to 2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 101: MEA Market Value (US$ Million) by Application, 2023 to 2033

Figure 102: MEA Market Value (US$ Million) by Technology Type, 2023 to 2033

Figure 103: MEA Market Value (US$ Million) by End Users, 2023 to 2033

Figure 104: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 109: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 110: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 111: MEA Market Value (US$ Million) Analysis by Technology Type, 2018 to 2033

Figure 112: MEA Market Value Share (%) and BPS Analysis by Technology Type, 2023 to 2033

Figure 113: MEA Market Y-o-Y Growth (%) Projections by Technology Type, 2023 to 2033

Figure 114: MEA Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 115: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 116: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 117: MEA Market Attractiveness by Application, 2023 to 2033

Figure 118: MEA Market Attractiveness by Technology Type, 2023 to 2033

Figure 119: MEA Market Attractiveness by End Users, 2023 to 2033

Figure 120: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Cancer Diagnostics Market

Published : August 2023

Healthcare

Lung Cancer Therapeutics Market

Published : June 2022

Healthcare

Tumor Tracking Systems Market

Published : March 2022

Explore Healthcare Insights

View Reports

Intratumoral Cancer Therapies Market